The good news is, though, that this opens up exciting new nutritional and interventional prospects for prevention
[DOI] [PubMed] [Google Scholar] 11.Lozic M., Stambolija V., Krezic I., Dugandzic A., Zivanovic-Posilovic G., Gojkovic S., Kovacevic J., Vrdoljak L., Mirkovic I., Kokot A., et al
Abstract Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes
This product is intended strictly for laboratory research purposes only
Overall, therefore, the main effects of GLP-1 are a reduction of fasting and postprandial blood glucose levels, lowering of body weight and protection from CVD, which are all therapeutic targets in type 2 diabetes (Fig
: : , 1 : L- - 1000 ( - 680 )